Avandia should be suspended, says European regulator

The diabetes drug Avandia (rosiglitazone) should be suspended from use in Europe, according to the European Medicines Agency (EMA).

The EMA recommended drugs Avandia, Avandamet and Avaglim should be suspended from sale in Europe. It follows a review of the evidence for safety of the drugs by the EMA’s Committee for Medicinal Products for Human Use (CHMP).

MHRA chief executive Professor Kent Woods said: 'Today’s suspension means that clinicians should review all patients currently on rosiglitazone and take appropriate action, according to the individual clinical situation, to change to another suitable treatment.’

The CHMP said data have suggested a possible increased risk of ischaemic heart disease associated with the use of rosiglitazone.

The committee concluded that ‘the benefits of rosiglitazone no longer outweigh its risks and recommended the suspension of the marketing authorisation of the medicines’.

As such, it will no longer be available in Europe within the next few months, unless further data showing benefit can be presented by the manufacturer.

Patients who are currently taking these medicines should make an appointment with their doctor to discuss suitable alternative treatments, the EMA said.

Patients are advised not to stop their treatment without speaking to their doctor.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GP training: Useful resources when preparing for the AKT

GP training: Useful resources when preparing for the AKT

Dr Branavan Anandasundaram highlights useful resources that GP trainees can use to...

GP training: How to succeed in the AKT

GP training: How to succeed in the AKT

Dr Branavan Anandasundaram passed the AKT earlier this year with a score of 89.5%....

Medico-legal: Advice on prescribing opioids

Medico-legal: Advice on prescribing opioids

The MDU's Dr Ellie Mein advises on how to avoid the medico-legal risks associated...

Map: How CQC ratings for general practice vary across England

Map: How CQC ratings for general practice vary across England

An overwhelming 95% of GP practices in England are rated either 'good' or 'outstanding'...

Rise in GP waiting times 'driving more patients to Google health advice'

Rise in GP waiting times 'driving more patients to Google health advice'

Longer waits for GP appointments may be pushing more patients to search for health...

GP locum rates continue to rise in most parts of the UK, poll reveals

GP locum rates continue to rise in most parts of the UK, poll reveals

Average hourly rates received by locums have risen across England over the past 12...